The pathogenesis of gastrointestinal (GI) dysmotility in scleroderma is incompletely understood, although previous studies have proposed a neuropathic mechanism. We studied patients with scleroderma as compared with other connective tissue disease patients and normal controls for the presence of circulating antibodies to myenteric neurons. Serial dilutions of sera were overlaid on rat intestine, doublelabeled with antineurofilament antibody as a myenteric plexus marker, and imaged using indirect immunofluorescence techniques. High titer sera ( -1:50) from 19 out of 41 scleroderma patients stained myenteric neurons, whereas none of 22 normals or 5 patients with idiopathic GI dysmotility were positive. Although 6 out of 20 SLE and 6 out of 10 mixed connective tissue disease patients' sera stained myenteric plexus neurons, when positive sera were absorbed with calf thymus extract to remove antinuclear antibody, 15 scleroderma sera, 0 SLE, and 2 mixed connective tissue disease patients retained positive staining of myenteric neurons. Western blotting using actin and neuronal intermediate filament preparations failed to show immunoreactivity with scleroderma sera containing antimyenteric neuronal antibodies. Paraneoplastic sera associated with GI dysmotility stained myenteric neurons in a different pattern than seen with scleroderma sera. A positive correlation between the presence of Raynaud's phenomenon and antimyenteric neuronal antibodies was observed in scleroderma patients. Our results indicate that IgG antibodies reacting with myenteric neurons are present in many patients with scleroderma. Although the neuronal antigen has not yet been identified, the presence of myenteric neuronal antibodies in patients with GI dysmotility and scleroderma suggests a neuropathic process. (J. Clin. Invest. 1994. 94:761-770.) 
Introduction
Autoantibodies have long been recognized in association with scleroderma but have not been related to the pathogenesis of the disease. Several novel autoantibodies present in serum of scleroderma patients such as anticentromere or anti-topoisomerase I (Scl-70) antibodies have been correlated with disease presentation (1) (2) (3) . Although specific disease manifestations vary in individual patients, various subgroups have been recognized, such as the CREST variant (Calcinosis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia)' which is often associated with the presence of anticentromere antibodies. Several novel autoantibodies found in scleroderma, including anti-RNA polymerase I, antifibrillarin, and anti-PM-Scl, are directed at antigens present in the nucleolus depending on cell function or cycle.
Gastrointestinal (GI) dysmotility can occur throughout the clinical spectrum of scleroderma diseases and sometimes occurs as the presenting manifestation. Although esophageal dysfunction is most often recognized, smooth muscle function throughout the entire GI tract may be affected. The pathogenesis of esophageal dysfunction and GI dysmotility in scleroderma is poorly understood. Association of Raynaud's phenomenon with GI dysmotility (4) suggests a common mechanism, such as autonomic dysfunction or microvascular pathology. Some patients, however, have been noted to have severe GI dysmotility without evidence for cutaneous disease, increase in esophageal fibrosis or connective tissue, or other manifestations most often recognized as scleroderma (5, 6) . Moreover, previous studies (7) (8) (9) have proposed a neuropathic mechanism to account for the GI dysmotility seen in these patients.
Paraneoplastic syndromes with GI dysmotility have been shown to be associated with the presence of circulating autoantibodies to the myenteric plexus (10) (11) (12) and may actually herald the appearance of the tumor. Although a distinct autoantibody has not been described in association with GI dysmotility in scleroderma, the possible involvement of autoantibody being directly related has never been explored carefully. Therefore, we undertook the present study for evidence of circulating antimyenteric neuronal antibodies in scleroderma patients.
Methods
Patients. 41 patients with scleroderma or a scleroderma-like connective tissue disorder who had positive antinuclear antibodies (ANAs) were prospectively selected from patients seen in the Rheumatology and Gastroenterology Clinics at the University of Florida Shands Hospital and at Arthritis Associates clinic in Gainesville, FL. Many of these patients had clinical, functional, or manometric evidence for GI dysmotility involving the esophagus and upper GI tract. The treating physician determined the appropriate GI tract workup in each patient. Clinical profiles of all patients studied are shown in Table I . Nine patients classified as definite scleroderma had the diagnosis confirmed by histo-1. Abbreviations used in this paper: ANA, antinuclear antibody; ANNA-1, antineuronal nuclear antibody, type 1; CREST, calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia; GI, gastrointestinal; MCTD, mixed connective tissue disease; NF-H, high-molecular-weight neurofilament protein; RNP, ribonucleoprotein. Other connective tissue disease patient controls. Sera from several groups of patients with other connective tissue diseases were also studied in parallel. These included 20 patients with rheumatoid arthritis and 20 patients with SLE who satisfied American College of Rheumatology criteria for definite disease (13, 14 ). An additional group of 10 patients with mixed connective tissue disease (MCTD) but without clinical fea-tures of scleroderma (Raynaud's phenomenon or GI dysmotility) was also studied.
Serology. Serum samples from patients were characterized in the laboratory for fluorescent ANA using mouse kidney sections and Hep-2 cell substrates, for associated serology using MOLT-4 (T-lymphocyte cell line) extracts for Western blots, and by double diffusion analysis for Scl-70 and ribonucleoprotein (RNP) antibody (15) . Three patients' sera were not available for such further characterization.
Tissue and indirect immunofluorescence. Healthy adult Harlan Sprague-Dawley rats were anesthetized and decapitated, and distal esophagus, stomach, small intestine, and colon were removed. Studies were approved by the University of Florida Animal Use Committee. Tissues were frozen in super-cooled isopentane at -80'C and mounted, and 5-8-pm cryostat sections were made longitudinally on a freezing microtome (model 327; International Equipment Co., Needham Heights, MA). Sections of longitudinal muscle and myenteric plexi were mounted on glass slides, fixed in acetone at -20'C for 5 min, and air-dried overnight before antibody labeling.
Serial dilutions (1:50, 1:100, 1:200, and 1:400) of test human serum were made using Tris-buffered saline (pH 7.0) and overlaid on prepared sections of rat ileum substrate. Because of the importance of phosphorylation affecting immunoreactivity with some antineuronal antibodies (16), phosphate-free Tris-buffered saline was used for all primary antibody dilutions. Polyclonal rabbit IgG anti-high-molecular-weight neurofilament (NF-H) antibody (17) (courtesy of Dr. Gerald Shaw, Department of Neurosciences, University of Florida) diluted 1:200 in Trisbuffered saline was used as a neuronal marker in double-labeling experiments. This antibody was produced by injecting rabbits with recombinant fusion protein NF-H and produces high titer neurofilament staining on rat brain substrate, specifically binding to purified NF-H subunits on immunoblots. Sections were incubated with samples of human and NF-H antisera as primary antibodies for double-labeled, indirect immunofluorescence microscopy as described previously (18 (22) and Shelanski (23) and actin prepared from chicken gizzard (Sigma Immunochemicals) and rat skeletal muscle (24).
Immunoblots. The intermediate filament preparation and actin protein were each transferred in 2x sample buffer with SDS to nitrocellulose after the method described by Towbin (25) using a Pharmacia Phastgel system (Uppsala, Sweden) (7.5% homogeneous gel, nonreducing conditions). Individual lanes were cut out of the nitrocellulose after appropriate blocking and incubated with mouse monoclonal antibodies for NF-H (NE14), medium-molecular-weight neurofilament (NN18), and glial fibrillary acidic protein (GA5), rabbit antiactin antibody (Sigma Immunochemicals), and six human sera positive for myenteric neuron staining (1:100-1:400 dilutions) as primary antibodies. Dilutions of 1:2,500 in 1% gelatin of peroxidase-conjugated goat F(ab' )2 antimouse, anti-human, or anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) were used as secondary antibodies.
Homogenates of rat brain in 5 ml of 50 mM Mes and 2 mM EGTA (Fig. 3) . There was not enough serum available for further studies in 1 of the 19 positive patients (patient 26). In three sera from scleroderma patients, calf thymus extract absorption abolished myenteric neuronal immunoreactivity. When positive sera in 10 scleroderma patients were absorbed with rat whole brain homogenate, in all 10 the myenteric plexus staining and Hep-2 cell antinuclear staining were both diminished; in many instances, one absorption with brain homogenate eliminated both antinuclear and antineuronal staining (Fig. 4) . The immunofluorescence pattern of staining seen with paraneoplastic sera was similar but clearly distinguishable as a different pattern (Fig. 5) from the staining demonstrated with the scleroderma sera ( Figs. 1 and 2 ).
The presence of Raynaud's phenomenon in scleroderma patients was significantly associated with antimyenteric neuronal antibodies in their sera (X2 = 14.9, P < 0.001). Of the scleroderma patients whose sera stained myenteric neurons, only one patient did not report Raynaud's phenomenon. Nucleolar Table II . The heterogeneity of antinuclear antibody reactivities among the positive scleroderma patients studied is shown in Fig. 6 (15) . Antibodies reacting with myenteric neurons were found not only in diffuse, generalized scleroderma, but also among patients with limited scleroderma, CREST, morphea, and a few patients with overlap syndromes or undifferentiated connective tissue disorders. 11 out of 16 patients with antibodies reacting with myenteric neurons showed clinical or laboratory manifestations of GI dysfunction, however, 19 out of 25 patients without demonstrable antimyenteric neuron antibodies also showed GI dysfunction (X2 = 1.6, P = NS).
None of the sera from 22 normals or 5 patients with idiopathic GI dysmotility stained myenteric neurons. In addition, none of the sera from 20 patients with clearcut rheumatoid arthritis showed positive staining. 6 sera from 20 SLE patients showed positive antimyenteric neuronal staining, but in each case absorption with thymus extract completely extinguished neuronal staining. 6 out of 10 MCTD patients' sera showed positive antimyenteric neuronal staining. After thymus extract serum absorption and whole brain homogenate absorption, two MCTD patients' sera still showed positive myenteric neuronal staining as well as persistent positive antinuclear staining with Hep-2 cells. Both of these patients showed extremely high ANA levels (1:5,120 and 1:20,480) and hypergammaglobulinemia.
Human serum which demonstrated positive immunoreactivity in myenteric neurons did not bind intermediate filaments or actin on Western blots. In parallel, polyclonal rabbit antiactin, mouse monoclonal anti-NF-H, anti-medium-molecularweight neurofilament protein, and anti-glial fibrillary acidic protein antibodies all showed strong positive Western blot staining on homologous substrates (data not shown).
Western blots of rat brain homogenates stained with positive scleroderma sera demonstrated weakly positive bands which clearly differed from the pattern of staining with paraneoplastic sera containing ANNA-1 antibody (data not shown). 766 Howe, Eaker, Sallustio, Peebles, Tan, and Williams 
Discussion
Positive fluorescent ANAs are found in 95-97% (27, 28) of patients with scleroderma, but the presence of myenteric neuronal antibodies in scleroderma has not been described previously. In the present study, we report for the first time that some patients with scleroderma have myenteric neuronal antibodies in their sera. The myenteric neuronal antibodies which we have described appear to be relatively unique for scleroderma or scleroderma-like connective tissue disease patients because we did not find the antibody in any normals or patients with idiopathic GI dysmotility. Moreover, the antibodies were not found in any of 20 rheumatoid arthritis patients. Although a few of the 20 patients with SLE demonstrated positive neuronal staining, in each instance the immunoreactivity was eliminated by thymus preabsorption suggesting nonneuronal specific ANA. 2 of the 10 patients with MCTD showed the presence of antimyenteric antibodies but were associated with extremely high titer ANA and, as opposed to scleroderma sera, did not extinguish with brain extract absorption.
Scleroderma sera with the myenteric neuronal antibodies, when absorbed by calf thymus extract, lost ANA reactivity on Hep-2 cell substrate but maintained a myenteric neuronal staining pattern in 15 out of 18 instances; thus, the antibodies which react with myenteric plexus in our patients are not demonstrating a nonspecific ANA reactivity but are antineuronal in specificity. This was further substantiated by our demonstration that whole rat brain homogenate effectively absorbed antimyenteric neuronal antibodies from test sera. In this regard, the absolute necessity for absorption of test sera with thymus extract to confirm specific neuronal staining was emphasized by our results, particularly with SLE sera where all apparent neuronal immunoreactivity was eliminated by thymus extract absorption. Anticytoskeletal antibodies in several immune-mediated diseases have been described but are relatively nonspecific, with circulating autoantibodies described in numerous disease states as well as in normals (19) (20) (21) (30) . Cohen (7) showed that the lower esophageal smooth muscular response was intact in scleroderma after testing with methacholine (directly acting at the cholinergic receptor), edrophonium (enhancing acetylcholine effects), and gastrin I (proposed to increase the release of acetylcholine), suggesting a primary neurogenic defect. A later study by Cohen's group (8) of duodenal myoelectric activity in patients with scleroderma suggested that impaired intrinsic cholinergic pathways in scleroderma were implicated, but the mechanism for such neuropathogenicity is unknown. The provocative response of enhanced propagating small bowel motility with octreotide reported in scleroderma patients (31) indirectly supports the hypothesis that the process is neuropathic because such organized small bowel motor activity is mediated via the myenteric plexus.
The severity and clinical presentation of GI dysmotility in scleroderma is variable and may remain clinically occult. One problem in a disease like scleroderma is that patients often have major abnormalities in GI function which are subclinical and only apparent after invasive recording techniques are applied. Some patients with minimal or no apparent skin disease, the most prominent and easily recognized sign associated with scleroderma, have severe GI dysmotility, and others with severe skin disease may not have clinically apparent GI dysmotility until they have had the disease for several years. Examination of Tables I and II indicate that, in fact, six of our patients, though strongly positive for antimyenteric neuronal antibodies, denied GI symptoms and did not undergo extensive motility testing. 90% of patients with scleroderma undergoing esophageal manometry during some course of their illness will demonstrate esophageal aperistalsis in the lower two-thirds of the esophagus (the smooth muscle portion) or decreased lower esophageal sphincter pressure (32) with or without subjective dysphagia. Since clinical GI tract symptoms do not necessarily reflect GI dysmotility, our inability to link the presence of myenteric plexus neuronal antibodies in patients with such GI symptoms is not surprising. Clearly, a prospective study of GI tract motility in scleroderma patients will be required to determine whether myenteric antibodies predict early, neuropathic-based dysmotility.
Lennon et al. (10) (11) (12) have reported that some patients with cancer have circulating antimyenteric neuronal antibodies in which pathophysiologic changes in intestinal neuromuscular function are linked. These patients developed clinically evident dysmotility in histologically normal intestine. Similarly, early in the course of scleroderma, motility may be disturbed in the presence of normal esophageal smooth muscle (33) . However, later on, at the extreme of disease, atrophy of smooth muscle, fibrosis of the submucosa and lamina propria, and thinning of the mucosa are seen. Even at that stage the myenteric plexus and skeletal muscle portions of the esophagus are pathologically normal at the light microscopic level (33, 34 scleroderma patients provide an attractive hypothesis to explain GI dysfunction on a neurogenic basis. The myenteric neuronal staining patterns, supported by preliminary Western blots, suggest a different neuronal antigen reactivity than recognized by ANNA-I antibody (10) (11) (12) . Our laboratories are pursuing studies to delineate the antigen(s) involved and the pathophysiologic significance of these observations in both animal and human studies in hope that this may shed some light on the poorly understood pathogenicity of scleroderma and provide a model for future therapy.
